REGULATORY

Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status

September 8, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A gastric cancer indication for Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) was reported to a key health ministry advisory panel on September 8, setting the stage for its official nod in around a month. The news bodes ill for its…

To read the full story

Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
MHLW Panel Backs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med and More
September 11, 2017

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…